-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $12.76
Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $12.76
Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) shares gapped up prior to trading on Wednesday . The stock had previously closed at $12.76, but opened at $13.60. Cullinan Oncology shares last traded at $12.84, with a volume of 148 shares.
Cullinan Oncology Stock Down 3.3 %
The company has a market cap of $547.34 million, a PE ratio of 5.40 and a beta of -0.09. The business's fifty day moving average is $12.64 and its 200-day moving average is $12.65.
Get Cullinan Oncology alerts:Insiders Place Their Bets
In other Cullinan Oncology news, insider Jennifer Michaelson sold 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of $12.40, for a total transaction of $49,600.00. Following the sale, the insider now owns 53,031 shares in the company, valued at approximately $657,584.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.50% of the stock is owned by company insiders.
Institutional Investors Weigh In On Cullinan Oncology
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rock Springs Capital Management LP raised its stake in Cullinan Oncology by 1.0% during the 1st quarter. Rock Springs Capital Management LP now owns 652,578 shares of the company's stock worth $6,832,000 after acquiring an additional 6,500 shares during the period. Dupont Capital Management Corp bought a new stake in Cullinan Oncology during the 1st quarter worth approximately $119,000. Victory Capital Management Inc. bought a new stake in Cullinan Oncology during the 3rd quarter worth approximately $538,000. Nisa Investment Advisors LLC raised its stake in Cullinan Oncology by 24.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 17,241 shares of the company's stock worth $222,000 after acquiring an additional 3,341 shares during the period. Finally, Silverarc Capital Management LLC raised its position in shares of Cullinan Oncology by 5.4% during the third quarter. Silverarc Capital Management LLC now owns 224,555 shares of the company's stock valued at $2,879,000 after buying an additional 11,465 shares during the last quarter. Institutional investors own 82.53% of the company's stock.Cullinan Oncology Company Profile
(Get Rating)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
See Also
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) shares gapped up prior to trading on Wednesday . The stock had previously closed at $12.76, but opened at $13.60. Cullinan Oncology shares last traded at $12.84, with a volume of 148 shares.
庫利南腫瘤學公司(納斯達克代碼：CGEM-GET Rating)的股價週三在交易前大幅上漲。該股此前收於12.76美元，但開盤報13.60美元。庫利南腫瘤學的股票最新報12.84美元，成交量為148股。
Cullinan Oncology Stock Down 3.3 %
庫利南腫瘤學股票下跌3.3%
The company has a market cap of $547.34 million, a PE ratio of 5.40 and a beta of -0.09. The business's fifty day moving average is $12.64 and its 200-day moving average is $12.65.
該公司市值為5.4734億美元，市盈率為5.40倍，貝塔係數為-0.09。該業務的50日移動均線切入位為12.64美元，200日移動均線切入位為12.65美元。
Insiders Place Their Bets
內部人士下注
In other Cullinan Oncology news, insider Jennifer Michaelson sold 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of $12.40, for a total transaction of $49,600.00. Following the sale, the insider now owns 53,031 shares in the company, valued at approximately $657,584.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.50% of the stock is owned by company insiders.
在庫利南腫瘤學的其他新聞中，內部人士詹妮弗·邁克爾森在9月27日星期二的一筆交易中出售了4000股該公司的股票。這些股票以12.40美元的平均價格出售，總成交額為49,600.00美元。出售後，這位內部人士現在擁有該公司53,031股，價值約657,584.40美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過此超鏈接。7.50%的股份由公司內部人士持有。
Institutional Investors Weigh In On Cullinan Oncology
機構投資者參與庫利南腫瘤學
Cullinan Oncology Company Profile
庫利南腫瘤學公司簡介
(Get Rating)
(獲取評級)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
庫利南腫瘤公司是一家生物製藥公司，專注於為美國的癌症患者開發一系列靶向腫瘤學和免疫腫瘤學療法。該公司的主要候選藥物是CLN-081，這是一種口服小分子藥物，正在進行I/IIa期劑量升級和擴大試驗，用於治療非小細胞肺癌患者。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
- 免費獲取StockNews.com關於庫利南腫瘤學的研究報告(CGEM)
- Verra移動庫存已返回空間站
- ASML的11月拉力賽有後勁嗎？
- 在盈利暴跌後，Advance Auto Parts是一筆買入嗎？
- BJ‘s批發俱樂部：當心賣方
- 馬倫汽車股票的下一個催化劑是12月23日
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受庫利南腫瘤學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對庫利南腫瘤學和相關公司的最新新聞和分析師評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧